Topical issues of cardiovascular risk scales application in cardiovascular disease clinical practice
AbstractCardiovascular risk assessment is an important and integral diagnostic stage for any cardiac patient. Despite the constant improvement of existing cardiovascular risk scales, many additional cardiovascular disease factors are still unaccounted. This review evaluates the advantages and disadvantages of using current scales, and examines the prognostic prospects for adding factors such as ongoing therapy, regional affiliation, socioeconomic status, and mental state.
Updating and improving cardiovascular risk scales is aimed at a patient-centered, personalized clinical approach.
Keywords:cardiovascular risk; scale; atherosclerosis; SCORE 2; CAD; patient-oriented approach
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Bakulin G.G., Serezhina E.K., Obrezan A.G. Topical issues of cardiovascular risk scales application in cardiovascular disease clinical practice. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2023; 11 (3): 43–52. DOI: https://doi.org/10.33029/2309-1908-2023-11-3-43-52 (in Russian)
References
1. Lindstrom M., DeCleene N., Dorsey H., et al. Global burden of cardiovascular diseases and risks collaboration. J Am Coll Cardiol. 2022; 80 (25): 2372–425. DOI: https://doi.org/10.1016/j.jacc.2022.11.001
2. Tsao C.T., Aday A.W., Almarzooq Z.I., et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023; 147 (8): e93–621. DOI: https://doi.org/10.1161/CIR.0000000000001123
3. Sattar N., Rawshani A., Franzén S., et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019; 139 (19): 2228–37. URL: https://doi.org/10.1161/CIRCULATIONAHA.118.037885
4. Comroy R.M., Pyörälä K., Fitzgerald A.P., et al.; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 (11): 987–1003. DOI: https://doi.org/10.1016/s0195-668x(03)00114-3
5. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., et al. Eurasian Association of Cardiology (EAC)/Russian National Atherosclerosis Society (RNAS, Russia) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Evraziyskiy kardiologicheskiy zhurnal [Eurasian Heart Journal]. 2020; (2): 6–29. DOI: https://doi.org/10.38109/2225-1685-2020-2-6-29 (in Russian)
6. Erina A.M., Usol’tsev D.A., Boyarinova M.A., et al. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2022; 27 (5). DOI: https://doi.org/10.15829/1560-4071-2022-5006 (in Russian)
7. Csenteri O., Jancsó Z., Szöllösi G.J., et al. Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2. Open Heart. 2022; 9 (2). DOI: https://doi.org/10.1136/openhrt-2022-002087
8. Shal’nova S.A. Comments on the section «Cardiovascular risk estimation» in the 2021 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2022; 21 (5): 67–71. DOI: https://doi.org/10.15829/1728-8800-2022-3171 (in Russian)
9. Kim J., You N.-Y., Lee J.-W., et al. Inverse association between statin use and overall cancer incidence in individuals with hypercholesterolemia, based on the Korean health insurance service between 2002 and 2015. Asia Pac J Public Health. 2019; 31 (2): 136–46. DOI: https://doi.org/10.1177/1010539519830235
10. Yourman L.C., Cenzer I.S., Boscardin W.J., et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA Intern Med. 2021; 181 (2): 179–85. DOI: https://doi.org/10.1001/jamainternmed.2020.6084
11. Kaasenbrood L., Boekholdt S.M., van der Graaf Y. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016; 134 (19): 1419–29. DOI: https://doi.org/10.1161/circulationaha.116.021314
12. Jensen J. Risk prediction: are we there yet? Circulation. 2016; 134 (19): 1441–3.
13. Pogosova N.V., Oganov R.G., Boytsov S.A., et al. Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (6): 67–78. DOI: https://doi.org/10.15829/1728-8800-2020-2739 (in Russian)
14. Cho S.M.J., Koyama S., Honigberg M.C., et al. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study. Eur Heart J. 2023; 44 (36): 3456–65. DOI: https://doi.org/10.1093/eurheartj/ehad380
15. Kaasenbrood L., Boekholdt S.M., van der Graaf Y. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016; 134 (19): 1419–29. DOI: https://doi.org/10.1161/circulationaha.116.021314
16. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (2): 104–12. DOI: https://doi.org/10.14341/DM2004116-17 (in Russian)
17. Sattar N., Rawshani A., Franzén S., et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019; 139 (19): 2228–37. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.037885
18. Kengne A.P., Patel A., Marre M., et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011; 18 (3): 393–8. DOI: https://doi.org/10.1177/1741826710394270
19. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023; 44 (28): 2544–56. DOI: https://doi.org/10.1093/eurheartj/ehad260
20. Salim S.V., Alonso A., Aparicio H.J., et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021; 143 (8): e254–743. DOI: https://doi.org/10.1161/cir.0000000000000950
21. Pal N., Sivaswamy N., Mahmod M., et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015; 132 (18): 1719–25. DOI: https://doi.org/10.1161/circulationaha.115.017119
22. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113 (11): 1424–33.
23. Regoli F., Scopigni F., Leyva F., et al. Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy. Eur J Heart Fail. 2013; 15 (2): 211–20.
24. Pocock S.J., Ariti C.A., McMurray J.J.V., et al. Predicting survival in heart failure: a risk score based on 39372 patients from 30 studies. Eur Heart J. 2013; 34 (19): 1404–13.
25. Braunwald E. Chronic heart failure: a look through the rear view mirror. Eur. Heart J. 2013; 34 (19): 1391–2.
26. Lee D.S., Austin P.C., Rouleau J.L., et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003; 26 (19): 2581–7.
27. Peterson P.N., Rumsfeld J.S., Liang L., et al. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010; 3 (3): 309–15.
28. Safavi K.C., Dharmarajan K., Kim N., et al. Variation exists in rates of admission to intensive care units for heart failure patients across hospitals in the United States. Circulation. 2013; 127 (8): 923–9.